Search

News Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis

How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of axSpA were recently published in the journal Therapeutic Advances in Musculoskeletal Disease as part of the extended clinical trial ESTHER.

Source: Arthritis 19. 4. 2022

News Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma –⁠ Case Study

The incidence of NDM-producing Klebsiella pneumoniae is increasing worldwide. NDM beta-lactamase is a significant cause of multidrug resistance in enterobacteria to various antibiotics, including carbapenems. Currently, the most suitable approach for the treatment of intestinal infections caused by NDM-producing K. pneumoniae is considered to be the combination of ceftazidime/avibactam with aztreonam. The following case study also illustrates its use in more complicated cases.

Source: Anti-Infectives 3. 3. 2023

News Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective

The I-WISh survey assessed the impact of immune thrombocytopenia (ITP) and its treatment on patients' lives. Patients identified fatigue as the most frequent, severe, and persistent symptom associated with ITP, unlike doctors who did not attribute such significance to this symptom. Recently published survey results also showed that patients need support from multiple sources, including doctors, family, friends, and patient groups.

Source: Immune Thrombocytopenia 22. 10. 2021

News Use of Medical Cannabis in Patients with Fibromyalgia to Relieve Pain and Depression

Medical cannabis is prescribed to patients with chronic pain resistant to conventional treatments. The efficacy of tetrahydrocannabinol (THC) therapy in patients with fibromyalgia syndrome (FMS) was recently evaluated in a German study.

Source: Medical Cannabis 22. 4. 2024

News Angiodysplasia as a Serious Problem in Patients with von Willebrand Disease −⁠ Case Study

Bleeding into the gastrointestinal tract can become a very significant cause of morbidity and mortality in patients with von Willebrand disease (vWD). It has been described that gastrointestinal (GI) bleeding associated with angiodysplasia is more common in individuals with vWD compared to other causes. Evidence suggests that von Willebrand factor (vWF) is associated with the regulation of angiogenesis, and its deficiency increases the risk of angiodysplasia. It is also known that this type of bleeding is difficult to treat because it is associated with recurrences. The following case study also very well illustrates and summarizes this issue.

Source: Von Willebrand Disease 19. 5. 2023

News Maintaining Therapeutic Doses of Levothyroxine Throughout Shelf Life

Levothyroxine is the drug of choice for patients with hypothyroidism. However, it is also one of the substances with a narrow therapeutic range, which increases the risk of overdose or underdose, especially in risk groups. An innovative formulation of levothyroxine guarantees the maintenance of the drug content within the range of 95–105% throughout the shelf life of the product.

Source: Thyroid Disorders 23. 2. 2022

News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics –⁠ Results of a Large Meta-Analysis

Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.

Source: Modern Treatment of Schizophrenia 24. 6. 2021

News Recommendations for the diagnosis of ITP in adults and children according to ASH guidelines

The American Society of Hematology (ASH) guidelines from 2019 highlighted several important aspects in the diagnosis and treatment of ITP that have remained unchanged from the 2011 guidelines.

Source: Immune Thrombocytopenia 22. 4. 2020

News Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis −⁠ True North Study Results

Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the treatment of ulcerative colitis (UC) in adult patients. We summarize the results of the phase III placebo-controlled True North study published in the New England Journal of Medicine, which demonstrated efficacy and safety in both induction and maintenance therapy for UC.

Source: Modulation of S1P in the Treatment of Autoimmune Diseases 9. 5. 2023

News Prediction of DM2 and CVD Development Risk Based on Lipidomic Risk Determination

The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.

Source: Modern Treatment of Diabetes 20. 5. 2022

Články časopisu Involvement of the gastrointestinal tract in amyloidosis: when to think about it and how to diagnose

Author of the article: Ryšavá R. Source: Gastroenterologie a hepatologie | 2/2019 23. 4. 2019

Články časopisu Beta-blockers in flow of time –⁠ view of an anaesthesiologist and intensivist

Author of the article: Karel Cvachovec Source: Časopis lékařů českých | 6/2010 21. 6. 2010

News Is it possible to predict survival time based on laboratory or radiological findings in patients with IPF?

High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also serve as a tool for more accurate prediction of survival time in IPF patients.

Source: Pulmonary Fibrosis 26. 11. 2020

News INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy

Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle proteins. How does targeted treatment for this disease work? We bring a concise, graphically processed overview of the efficacy and mechanism of action of the first selective cardiac myosin inhibitor.

Source: Hypertrophic Cardiomyopathy (HCM) 17. 5. 2024

News Current Therapy Options for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a chronic progressive disease that exclusively affects adults, predominantly of middle and older age. Until recently, the disease was practically untreatable. However, this has changed with the discovery of antifibrotic drugs, which have significantly altered the prognosis for patients. Early diagnosis and initiation of therapy at a specialized center, of which there are several in the Czech Republic, are essential for success.

Source: Pulmonary Fibrosis 4. 6. 2020